Potential Benefits: Significant Weight Loss: When combined with GLP-1 therapy, Cagrilintide has led to greater reductions in body weight than GLP-1s alone in clinical trials
Focus on Electrolytes Water alone is sometimes not enough, especially if you are active or experiencing GI issues
Coverage is limited to FDA-approved uses like type 2 diabetes, reducing cardiovascular risk, or treating sleep apnea
We'll explore the mechanisms of action behind Mounjaro, its administration, potential side effects, and its role in a comprehensive weight loss strategy
Slowing the ramp to the label cadence (2.5 mg start, 2.5 mg steps, four-week holds) dropped that to mid-single digits at every maintenance dose, at no cost to the 12-week result, and the dedicated slow-titration trial reached placebo range. Reaching 15 mg is not the problem